In its announcement, Abiomed shared the story of one specific 42-year-old COVID-19 patient who was able to fully recover and return to work thanks to ECpella. That patient’s cardiologist was John Finlay, MD, of Mercy Catholic Medical Center-Fitzgerald Campus in Darby, Pennsylvania. Finlay spoke with Abiomed about the experience. “It is remarkable…
Creating these complex structures with 3D printing alone has never been possible—until now.
The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”
Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis.
Overall, the recall includes 7,799 blood tests intended to help physicians identify early signs of a myocardial infarction.
The new 44-page document focuses on the detection, classification and risk assessment of congenital heart issues.
CMS also floated the idea of pausing the AUC program until a better implementation strategy could be put into place.
The 2023 Cardiovascular Business Salary and Job Satisfaction Report is here! We surveyed cardiologists, interventional cardiologists, nurses, service line mangers, coders and others in the industry…
The new-look devices are soft, flexible, transparent and roughly the size of a postage stamp.
Versanis, founded in 2021 by a venture capital firm, is primarily known as the company behind the obesity drug bimagrumab.
The American Society of Echocardiography recognized the lack of training and standardization for point-of-care ultrasound users and decided to do something about it.
